Tenascin-C, proliferation and subendothelial fibronectin in progressive pulmonary vascular disease.
about
Molecular pathogenesis of pulmonary arterial hypertensionRegulation of tenascin-C, a vascular smooth muscle cell survival factor that interacts with the alpha v beta 3 integrin to promote epidermal growth factor receptor phosphorylation and growthImmune and inflammatory mechanisms in pulmonary arterial hypertensionTransglutaminase 2-mediated serotonylation in pulmonary hypertensionLinking a serotonin transporter polymorphism to vascular smooth muscle proliferation in patients with primary pulmonary hypertensionWnt signaling regulates smooth muscle precursor development in the mouse lung via a tenascin C/PDGFR pathwayCalpain mediates pulmonary vascular remodeling in rodent models of pulmonary hypertension, and its inhibition attenuates pathologic features of diseaseProteomics of transformed lymphocytes from a family with familial pulmonary arterial hypertension.S100A4 and bone morphogenetic protein-2 codependently induce vascular smooth muscle cell migration via phospho-extracellular signal-regulated kinase and chloride intracellular channel 4Genomewide RNA expression profiling in lung identifies distinct signatures in idiopathic pulmonary arterial hypertension and secondary pulmonary hypertension.Erythropoietin upregulation in pulmonary arterial hypertensionInflammation and immunity in the pathogenesis of pulmonary arterial hypertensionApoptosis in the vasculature: mechanisms and functional importance.Reversal of experimental pulmonary hypertension by PDGF inhibition.Predicting rates of cell state change caused by stochastic fluctuations using a data-driven landscape model.ClC-3 chloride channel is upregulated by hypertrophy and inflammation in rat and canine pulmonary artery.S100A4/Mts1 produces murine pulmonary artery changes resembling plexogenic arteriopathy and is increased in human plexogenic arteriopathyAdvances in tenascin-C biology.Tenascin C expression is upregulated in pancreatic cancer and correlates with differentiationCompartment-specific expression of collagens and their processing enzymes in intrapulmonary arteries of IPAH patientsMatrix metalloproteinase-2 is associated with tenascin-C in calcific aortic stenosisDevelopment of occlusive neointimal lesions in distal pulmonary arteries of endothelin B receptor-deficient rats: a new model of severe pulmonary arterial hypertensionSerotonylated fibronectin is elevated in pulmonary hypertensionTenascin-C expression in invasion border of early breast cancer: a predictor of local and distant recurrence.Pulmonary arterial remodeling induced by a Th2 immune responseHypoxia-induced mitogenic factor (HIMF/FIZZ1/RELMα) in chronic hypoxia- and antigen-mediated pulmonary vascular remodeling.Suppression subtractive hybridization identifies distinctive expression markers for coronary and internal mammary arteriesMolecular pathogenesis of pulmonary arterial hypertensionIn Pulmonary Arterial Hypertension, Reduced BMPR2 Promotes Endothelial-to-Mesenchymal Transition via HMGA1 and Its Target SlugType A dissection and chronic dilatation: tenascin-C as a key factor in destabilization of the aortic wall.Transgenic expression of human matrix metalloproteinase-9 augments monocrotaline-induced pulmonary arterial hypertension in miceTargeted expression of heme oxygenase-1 prevents the pulmonary inflammatory and vascular responses to hypoxia.The 'sweet' and 'bitter' involvement of glycosaminoglycans in lung diseases: pharmacotherapeutic relevance.Thrombin induces fibronectin-specific migration of pulmonary microvascular endothelial cells: requirement of calcium/calmodulin-dependent protein kinase IISuppression of the expression of hypoxia-inducible factor-1α by RNA interference alleviates hypoxia-induced pulmonary hypertension in adult rats.Cellular and molecular basis of pulmonary arterial hypertension.Reversible or irreversible remodeling in pulmonary arterial hypertension.Anticipated classes of new medications and molecular targets for pulmonary arterial hypertensionTenascin-C in cardiovascular remodeling: potential impact for diagnosis, prognosis estimation and targeted therapy.LC3-mediated fibronectin mRNA translation induces fibrosarcoma growth by increasing connective tissue growth factor
P2860
Q24634317-1F0D2749-A9DA-42B5-963B-B343936F49D2Q24678669-3D1A733A-7D59-4AD7-B1C2-99948F6CD76AQ26851508-1715716F-CEC3-4028-BF99-C475AC0BDAF5Q27027862-2F7A4A80-748D-470D-B329-E332ECB15707Q28361811-A3EA11DF-740A-4EA9-B5D1-8975DD16C16EQ28586021-D7D22F8C-324F-4E54-A883-DA361AD94772Q30429980-AB2FEAFC-1EC5-4E5D-B313-114AA626C376Q33302400-EA61AFFA-4414-4A03-9B0F-30B7384AB164Q33636296-6EC30542-7D18-47D4-9443-E46CF4962F4FQ33784417-3A7E306B-BACC-4F23-A03C-02D29CC97882Q33805982-697C6B82-BBDF-4717-9ABF-DAB37104C008Q33898213-595A2304-2E3C-4DCD-B654-5FC6C4C173B9Q33959479-EA068AAF-76C2-4B63-8FE2-1409C18B0E02Q34048479-41C9D6AD-6530-4CF0-A7BC-D5DA97E59FFBQ34463339-84CFBE66-3E9E-42A3-8F1D-166B550C749DQ35048823-77412A66-761B-45E6-9DAB-D8753FE68F38Q35083293-78BE0E18-00F4-4711-A27B-60F2603EE26FQ35214557-7C3C0105-9B97-46B4-9BAF-FA3F3D262530Q35588136-BD0D9E61-1A67-4601-9EEC-AD3DDD530510Q35595010-83B7E361-48B5-4BBB-BE9E-4A31A59DAC3BQ35746579-79CCC989-699A-45E9-B632-14E0E4239B6BQ35916976-276FA995-F1CD-4F96-B2A2-129CED026F48Q36045577-B59A46B4-19D3-42F9-8897-FFD14AEE580DQ36115781-BE5ECBBB-40F3-44AE-B7DE-AF0E7398764EQ36502869-C5E907E0-EFF3-4DB7-BF59-C6EDA6A5D6B4Q36541868-A24CA66B-4011-4AD0-8C18-D06F432ACB01Q36630287-CA289104-7C0B-45B7-B6E0-6A53A12A4387Q36736065-3B4CDC29-3590-45DA-B495-512EE3DBF0CDQ36869381-E7144562-DB45-4FE8-B297-2DA3D2A0E4D3Q37024218-B820FBBF-8E7F-43F2-8F04-34FA77BAB142Q37100760-B4667DF1-4995-4E0E-92EF-68AC967D224FQ37115911-A26BA3CF-21A1-4C3A-83AD-6A02E0DAD330Q37346515-AB10B19D-5A71-41ED-8664-203FAAB5C69DQ37406387-BA08F0BE-A0D5-4C00-BD30-B59959F6B7B7Q37426657-70E0583D-EDCE-4E3C-BFC8-DFDD46F48FB1Q37465320-0A462494-72A0-4E89-B3E1-E1AE98AEDDCEQ37653353-5168E1EA-B3C5-4806-8129-675D5644F351Q38105550-7F8D2086-BE70-46B4-B79E-18AC72C0D4DCQ38308741-17995829-CEF7-4F17-9303-8B3D5306C0BDQ38355075-3D0E9CA7-7CAC-452C-ADC4-929CC4CC8E21
P2860
Tenascin-C, proliferation and subendothelial fibronectin in progressive pulmonary vascular disease.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Tenascin-C, proliferation and ...... ve pulmonary vascular disease.
@ast
Tenascin-C, proliferation and ...... ve pulmonary vascular disease.
@en
type
label
Tenascin-C, proliferation and ...... ve pulmonary vascular disease.
@ast
Tenascin-C, proliferation and ...... ve pulmonary vascular disease.
@en
prefLabel
Tenascin-C, proliferation and ...... ve pulmonary vascular disease.
@ast
Tenascin-C, proliferation and ...... ve pulmonary vascular disease.
@en
P2093
P2860
P1476
Tenascin-C, proliferation and ...... ive pulmonary vascular disease
@en
P2093
P2860
P304
P407
P577
1997-04-01T00:00:00Z